Cencora (COR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
14 Jun, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of eleven directors at the 2025 Annual Meeting scheduled for March 6, 2025.
An advisory vote will be held to approve the fiscal 2024 compensation of named executive officers.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2025 is on the agenda.
Proxy holders may vote on other business that may properly come before the meeting.
Board of directors and corporate governance
Eleven nominees are presented for election to the board, including individuals with diverse backgrounds and expertise.
Executive compensation and say-on-pay
Shareholders are asked to provide an advisory vote on the compensation of named executive officers for fiscal 2024.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cencora
- Specialty pharma and MSO growth drive long-term profitability, with stable contracts through 2029.COR
2026 Global Healthcare Conference - Specialty-driven growth and MSO integration position the business for sustained momentum through 2027.COR
Morgan Stanley 24th Annual Global Healthcare Conference - Specialty growth, biosimilars, and MSO expansion fuel strong performance amid stable partnerships.COR
Wells Fargo 21st Annual Healthcare Conference - Q3 FY2026 saw 5.1% revenue growth, higher EPS, and raised guidance, with $1B in share buybacks.COR
Q3 2026 - Raised guidance and specialty investments drive strong growth and long-term confidence.COR
Barclays 28th Annual Global Healthcare Conference - Guidance reaffirmed, growth to accelerate, $1B buybacks planned, and AI-driven efficiencies prioritized.COR
Bank of America Global Healthcare Conference 2026 - Q2 FY2026 delivered 3.8% revenue growth, higher EPS, and a $1.1B OneOncology gain.COR
Q2 2026 - Adjusted EPS and revenue climbed double digits, with 2025 growth and RCA deal ahead.COR
Q4 2024 - Specialty growth, biosimilars, and disciplined capital deployment drive strong performance.COR
43rd Annual J.P. Morgan Healthcare Conference